September 27, 2017
12:00 pm to 1:00 pm

3695 Med. Sci. II (North Lecture Hall)


Anice Lowen Ph.D.
Assistant Professor
Department of Microbiology and Immunology
Emory University School of Medicine, Atlanta, Georgia
September 27, 2017
4:00 pm to 5:00 pm

5623 Med. Sci. II  (Wheeler Seminar Room)

Miranda Gray, Ph.D.
F1000 Outreach Manager

F1000 Resources for Communication, and how Open Science is Revolutionizing Science Publishing

September 28, 2017
12:00 pm to 1:00 pm

5330 Medical Science I

Michael Grigg, Ph.D.
Chief, Molecular Parasitology Section
Laboratory of Parasitic Diseases
National Institutes of Health, NIAID
October 3, 2017
10:00 am to 11:00 am


Chyung Ru Wang, Ph.D.
Department of Microbiology and Immunology
Feinberg School of Medicine
Northwestern University, Chicago, Illinois
October 4, 2017
9:00 am to 10:00 am

5623 Med. Sci. II  (Wheeler Seminar Room)

Rebecca Pollet, Ph.D.
Postdoctoral Fellow - Koropatkin Lab

The intestinal microbiota encode millions of genes that represent unique pharmaceutical targets for human diseases from neurological disorders to drug toxicity. We are interested in the role the intestinal microbiota play in reactivating compounds that have been inactivated through glucuronidation in the liver. In particular, the chemotherapy drug CPT-11, or irinotecan, is inactivated by UGTs in the liver and then reactivated by bacterial b-glucuronidase (GUS) enzymes in the large intestine resulting in dose-limiting diarrhea.

October 9, 2017
12:00 pm to 1:00 pm


Heran Darwin, Ph.D.
Department of Microbiology
NYU Langone Health, New York City
October 11, 2017
12:00 pm to 1:00 pm

BSRB Seminar Rooms A, B, and C

Takamasa Inoue, Ph.D.
Research Investigator
Department of Cell and Developmental Biology
October 18, 2017
3:30 pm to 4:30 pm

Great Lakes North, Palmer Commons Building

Yang-Yu Liu, Ph.D.
Assistant Professor, Harvard Medical School
Associate Scientist, Brigham and Women's Hospital

We coexist with a vast number of microbes—our microbiota—that live in and on our bodies, and play an important role in human physiology and diseases. Propelled by metagenomics and next-generation DNA sequencing technologies, many scientific advances have been made through the work of large-scale, consortium-driven metagenomic projects. Despite these advances, there are still many fundamental questions regarding the dynamics and control of microbiota to be addressed.

October 30, 2017
12:00 pm to 1:00 pm


Ekaterina Heldwein, Ph.D.
Associate Professor of Molecular Biology and Microbiology
Sackler School of Biomedical Graduate Sciences
Tufts University, Boston, Massachusetts
November 1, 2017
12:00 pm to 1:00 pm


Gunnar C. Hansson, Ph.D.
Chairman Swedish Mass Spectrometry Society (SMSS)
Department of Medical Biochemistry
University of Gothenburg
Gothenburg, Sweden